Brazil's New MedTech Shortcut: Pure Global on ANVISA's Reliance Gambit

This week, we dive into a game-changing regulatory shift in Latin America's largest MedTech market. Brazil's ANVISA has just launched a new "reliance pathway," promising to dramatically accelerate market access for high-risk medical devices that have already been approved by authorities like the US FDA. This could slash years off of registration timelines. In this episode, we unpack the reality behind the hype. We explore the massive opportunities this creates for international manufacturers and the critical details that could make or break a successful submission. Learn what "essentially identical" really means for your product and why local compliance is more important than ever, even with this new shortcut. **What You'll Learn:** 1. What is ANVISA's new reliance pathway and which foreign approvals are accepted? 2. How much faster can your Class III or IV device get to market under this new rule? 3. What are the most common "hidden hurdles" that could disqualify you from the optimized review? 4. Does your product's indication for use perfectly match your foreign approval? 5. Why is a local Brazil Registration Holder (BRH) still absolutely essential for success? 6. How does this change the strategic importance of Brazil in your global expansion plans? 7. What are the key differences between the reliance dossier and a standard submission? Navigating regulatory shifts like Brazil's new reliance pathway is critical for market success. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI to streamline market access across more than 30 countries. Let us be your local representative in Brazil and ensure your submission is optimized for the fastest possible approval. Contact us at [email protected] or visit https://pureglobal.com/ to secure and accelerate your market presence.